相关实验视频

Updated: Sep 18, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

基于1,3,4-oxadiazole的EGFR抑制剂的设计,合成和评估

Zijun Tang¹, Mingxing Hu², Ye Gan³

¹Guangxi Key Laboratory of Special Biomedicine; School of Medicine, Guangxi University, Nanning, 530004, PR China; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, 610041, PR China.

Bioorganic & medicinal chemistry letters

|June 24, 2025

概括

一种基于1,3,4-氧沙的新型化合物4b,对EGFR T790M突变产生强烈的抑制,这是一个关键的耐药性机制. 这种化合物有效向EGFR耐药癌症,抑制细胞迁移,并诱导细胞循环停止.

科学领域:

药用化学医学化学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

表皮生长因子受体 (EGFR) 是癌症治疗的关键标.
对EGFR抑制剂的获得性耐药性,特别是T790M突变,是一个重大的临床挑战.
需要新的治疗策略来克服EGFR突变癌症的耐药性.

研究的目的:

设计和合成新型EGFR抑制剂,其中包括1,3,4-oxadiazole部分.
评估这些化合物对EGFR突变的疗效,特别是T790M.
为了研究化合物的抗癌作用,4b.

主要方法:

将1,3,4-oxadiazoles集成到quinazoline支架中,以创建新的EGFR抑制剂.
在体外生化测试以确定对EGFR突变的抑制度 (IC50).
基于细胞的测试,以评估对细胞迁移和细胞周期进展的影响.

主要成果:

与埃尔洛丁尼布相比,化合物4b对EGFR L858R/T790M突变体表现出更高的功效.
4b在A431和NCI-H1975细胞中显著抑制了细胞迁移.
在NCI-H1975细胞中使用4b诱导的G1阶段细胞周期停止治疗.

结论:

化合物4b是一种强大的EGFR抑制剂,向T790M耐药性突变.
4b显示出有前途的抗迁移和细胞循环破坏性质.
4b 是一种潜在的化合物,可用于开发抗EGFR耐药肺癌的新疗法.

关键词:

一,三,四-氧化二醇.活动评估活动评估.癌症癌症癌症癌症欧洲农业基金会 (EGFR) 是一个.抑制剂的抑制剂

更多相关视频

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...